OPTICAL POINT-OF-CARE DIAGNOSTICS: Noninvasive approach to Alzheimer's assessment promises early diagnosis

"Our vision is to change the course of Alzheimer's disease by enabling early diagnosis at the point of care," Paul Hartung, president and CEO of Cognoptix (Acton, MA) told analysts at the 9th Annual Lux Executive Summit: Seizing the Innovation Initiative (March 31, 2014, Boston, MA). In February, Cognoptix announced that the strong results of a multisite clinical trial of its SAPPHIRE II eye test, which is designed to identify Alzheimer's disease (AD) patients via a beta-amyloid (Ab) signature in their eyes, were published in the Journal of Alzheimer's Disease & Other Dementias (AJA).

"We have made great progress," Hartung added, "in developing an early-stage, noninvasive diagnostic test for AD designed to allow treatment to start before significant neuronal loss and irreversible brain damage occur."

Hartung, who orchestrated the first-ever Series A syndicated Angel deal in the Northeast, has closed Seed, Series A, Series B, and Series C rounds of financing for Cognoptix totaling $17 million with an international Angel and VC syndicate. He has extensive management experience launching successful startup businesses and leading Fortune 500 organizations.

According to the Alzheimer's Association, while physicians can almost always determine whether a person has dementia, it may be difficult to determine the cause. Cognoptix is focused on developing and commercializing an in-office, drug/device diagnostic system as an aid in the early detection of Alzheimer's disease. Its investors include Inventages Venture Capital, one of the world's largest life sciences-, nutrition-, and wellness-focused venture capital firms; Launchpad Venture Group, a Boston-based Angel investment firm that provides funding to early-stage companies; and Maine Angels, accredited private equity investors in promising New England entrepreneurs and companies. SAPPHIRE II is approved for investigational use only in the United States.

Get All the BioOptics World News Delivered to Your Inbox

Subscribe to BioOptics World Magazine or email newsletter today at no cost and receive the latest news and information.

 Subscribe Now
Related Articles

Merz acquires laser tattoo removal device maker ON Light Sciences

Merz North America has acquired ON Light Sciences, which develops technologies to enhance laser-based dermatology procedures.

Shortwave-infrared device could improve ear infection diagnosis

An otoscope-like device that could improve ear infection diagnosis uses shortwave-infrared light instead of visible light.

Laser therapy extracts rare tumor that grew human hair, skin in boy's skull

About four years ago, a tumor comprised of human skin, hair, bone and cartilage was fast-growing inside a Ramsey, MN, 10-year-old youth's brain.

Low-level laser therapy could speed muscle recovery at Rio 2016 Olympics

The gold medal-winning women’s U.S. Gymnastics team is reportedly experimenting with infrared light therapy to alleviate pain and reduce swelling in its athletes. (Update: A spokesperson for ...

Neuro15 exhibitors meet exacting demands: Part 2

Increasingly, neuroscientists are working with researchers in disciplines such as chemistry and p...

Why be free?

A successful career contributed to keeping OpticalRayTracer—an optical design software program—fr...

LASER Munich 2015 is bio-bent

LASER World of Photonics 2015 included the European Conferences on Biomedical Optics among its si...

White Papers

Understanding Optical Filters

Optical filters can be used to attenuate or enhance an image, transmit or reflect specific wavele...

How can I find the right digital camera for my microscopy application?

Nowadays, image processing is found in a wide range of optical microscopy applications. Examples ...



Twitter- BioOptics World